Cardiovascular Endocrinology and Metabolism: Theory and Practice of Cardiometabolic Medicine discusses the close intersection between metabolic disorders and cardiovascular disease; covering the basic science and pathophysiology of disease and the latest research in pharmacological approaches and translational therapeutic options. This book is a valuable resource for the vascular and endocrinology clinical and research communities in need of knowledge and potential outcomes.
The global increase in the prevalence of cardiometabolic disorders; and the introduction of therapeutic options for treating metabolic disease that also lower cardiovascular risk; is bringing endocrinologists and cardiologists together in a shared clinical experience.
1. Introduction - p. xxv 2. Chapter 1 Obesity and insulin resistance: routes to vascular disease - p. 3 3. Chapter 2 Diabetes mellitus and macrovascular disease: epidemiology and cardiovascular risk assessment - p. 11 4. Chapter 3 Complex metabolic–endocrine syndromes: associations with cardiovascular disease - p. 39 5. Chapter 4 Hypertension: pathophysiology and relevance to the cardiometabolic syndrome - p. 83 6. Chapter 5 Lipids, atherosclerosis, and microvascular disease: Translating basic science into pharmacotherapeutics - p. 97 7. Chapter 6 Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: pathophysiology and implications for cardiovascular disease - p. 137 8. Chapter 7 Cardiac energy metabolism in heart failure - p. 175 9. Chapter 8 Hemostatic abnormalities associated with diabetes and their clinical implications - p. 199 10. Chapter 9 Type 2 diabetes management: from a glucose-centric approach to cardio-renal risk reduction - p. 221 11. Chapter 10 Classic endocrine disorders: implications for cardiovascular disease - p. 233 12. Chapter 11 The fundamental role of obesity management in cardiometabolic risk reduction: nonpharmacological, pharmacological, and surgical approaches - p. 273 13. Chapter 12 Diabetes: evolution of multifactorial vascular risk reduction - p. 311 14. Chapter 13 Sodium-glucose Co-transporter-2 inhibitors: a new era of cardioprotection and renoprotection - p. 337 15. Chapter 14 Glucagon-like peptide-1 receptor agonists: role in the prevention and treatment of diabetes-related cardiovascular complications - p. 365 16. Chapter 15 Hypertension and the metabolic syndrome: toward personalized management - p. 397 17. Chapter 16 Proprotein convertase subtilisin kexin type 9 inhibitors and other novel lipid-modifying drugs: broadening the perspective of cardiovascular disease prevention - p. 427 18. Chapter 17 Heart failure: pathophysiology and the emergence of novel therapies - p. 441 19. Chapter 18 Interventional treatment of atherosclerotic heart disease - p. 459 20. Chapter 19 Peripheral arterial disease and the cardiometabolic syndrome: assessment and management - p. 469 21. Index - p. 491
Cardiovascular Endocrinology and Metabolism: Theory and Practice of Cardiometabolic Medicine discusses the close intersection between metabolic disorders and cardiovascular disease; covering the basic science and pathophysiology of disease and the latest research in pharmacological approaches and translational therapeutic options. This book is a valuable resource for the vascular and endocrinology clinical and research communities in need of knowledge and potential outcomes.
The global increase in the prevalence of cardiometabolic disorders; and the introduction of therapeutic options for treating metabolic disease that also lower cardiovascular risk; is bringing endocrinologists and cardiologists together in a shared clinical experience.
1. Introduction - p. xxv 2. Chapter 1 Obesity and insulin resistance: routes to vascular disease - p. 3 3. Chapter 2 Diabetes mellitus and macrovascular disease: epidemiology and cardiovascular risk assessment - p. 11 4. Chapter 3 Complex metabolic–endocrine syndromes: associations with cardiovascular disease - p. 39 5. Chapter 4 Hypertension: pathophysiology and relevance to the cardiometabolic syndrome - p. 83 6. Chapter 5 Lipids, atherosclerosis, and microvascular disease: Translating basic science into pharmacotherapeutics - p. 97 7. Chapter 6 Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: pathophysiology and implications for cardiovascular disease - p. 137 8. Chapter 7 Cardiac energy metabolism in heart failure - p. 175 9. Chapter 8 Hemostatic abnormalities associated with diabetes and their clinical implications - p. 199 10. Chapter 9 Type 2 diabetes management: from a glucose-centric approach to cardio-renal risk reduction - p. 221 11. Chapter 10 Classic endocrine disorders: implications for cardiovascular disease - p. 233 12. Chapter 11 The fundamental role of obesity management in cardiometabolic risk reduction: nonpharmacological, pharmacological, and surgical approaches - p. 273 13. Chapter 12 Diabetes: evolution of multifactorial vascular risk reduction - p. 311 14. Chapter 13 Sodium-glucose Co-transporter-2 inhibitors: a new era of cardioprotection and renoprotection - p. 337 15. Chapter 14 Glucagon-like peptide-1 receptor agonists: role in the prevention and treatment of diabetes-related cardiovascular complications - p. 365 16. Chapter 15 Hypertension and the metabolic syndrome: toward personalized management - p. 397 17. Chapter 16 Proprotein convertase subtilisin kexin type 9 inhibitors and other novel lipid-modifying drugs: broadening the perspective of cardiovascular disease prevention - p. 427 18. Chapter 17 Heart failure: pathophysiology and the emergence of novel therapies - p. 441 19. Chapter 18 Interventional treatment of atherosclerotic heart disease - p. 459 20. Chapter 19 Peripheral arterial disease and the cardiometabolic syndrome: assessment and management - p. 469 21. Index - p. 491
